Previous 10 | Next 10 |
Regeneron announces FDA approval for Ebola treatment REGN-EB3. Pluristem receives approval for Cohort II of Chronic Graft vs. Host Disease Study. AnaptysBio announces positive data from Phase 3 Imsidolimab trial. For further details see: Regeneron's Ebola Approval, And O...
Pluristem Therapeutics (PSTI) has received clearance from the safety committee of an investigator initiated Phase I/II study to move forward with patient enrollment for cohort II.The study will evaluate PLX-PAD cells in the treatment of steroid-refractory chronic graft vs. host disease (GvHD)...
HAIFA, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological products, today announced that it has received clearance from the safety committee of an...
Taiwan Liposome (TLC) +89% after company secures Australian and Taiwan approval to initiate trial of inhaled malaria drug for COVID-19.Ocean Power Technologies (OPTT) +47%.Sunworks (SUNW) +45% on announcing $10M in Q3 project wins.Urban Tea (MYT) +31%.Hill International (H...
Pluristem Therapeutics (PSTI) has received approval from the Israeli Ministry of Health to commence patient enrollment in Israel for its COVID-19 Phase II clinical trial, under the protocol that was approved by the Germany’s regulatory agency.A total of 40 patients hospitalized with se...
HAIFA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that it has received approval from the Israe...
Clover Wolf Capital who owns more than 10% of Pluristem Therapeutics (PSTI) bought additional 199,219 common shares for transaction value of $2M.Shares are up 1.8% in premarket. For further details see: Pluristem Therapeutics up on insider buy
The Malta Conferences address the shared desire to improve quality of life and political stability in the Middle East through scientific collaboration HAIFA, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- On Wednesday, September 30, 2020, Pluristem Therapeutics Inc. (Nasdaq:PSTI)...
Pluristem Therapeutics (NASDAQ: PSTI ) issues shareholder update . More news on: Pluristem Therapeutics Inc., Healthcare stocks news, Read more ...
HAIFA, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) , a leading regenerative medicine company developing a platform of novel biological products, today issued an update to its shareholders from its Chief Executive Officer and Presid...
News, Short Squeeze, Breakout and More Instantly...
Pluristem Therapeutics Inc. Company Name:
PSTI Stock Symbol:
NASDAQ Market:
Pluristem Therapeutics Inc. Website:
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executi...
As of July 26 , 2022 , Pluri ’s stock will trade under the symbol PLUR The new name reflects the Company ’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cel...
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, Ju...